Focus: Rallybio is a publicly traded oncology-focused biotechnology company headquartered in New Haven, CT, currently in early-stage clinical development with minimal revenue generation.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Rallybio to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Rallybio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rallybio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
If You Invested $1,000 in Rallybio Corp (RLYB) - Stock Titan
If You Invested $1,000 in Rallybio Corp (RLYB) Stock Titan
Candid lists via Rallybio reverse merger, adds $505m financing - The Pharma Letter
Candid lists via Rallybio reverse merger, adds $505m financing The Pharma Letter
Rallybio to acquire Candid Therapeutics - Pharmaceutical Technology
Rallybio to acquire Candid Therapeutics Pharmaceutical Technology
Candid, in a reverse merger with RallyBio, to go public - BioPharma Dive
Candid, in a reverse merger with RallyBio, to go public BioPharma Dive
TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio - Fierce Biotech
TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio Fierce Biotech
Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline - MedCity News
Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline MedCity News
Showing 6 of 8 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo